Seo Jung-jin is a South Korean businessman, the self-made billionaire Co-founder and Executive Chairman of Celltrion Group (KRX: 068270), a global leader in biopharmaceuticals and biosimilar drugs. His career is rooted in biotechnology, pharmaceuticals, and entrepreneurial audacity.

Seo holds a Master's degree in Business Administration from Korea Advanced Institute of Science and Technology (KAIST). His philosophical approach centers on technological excellence, scale manufacturing, and long-term commitment to affordable, high-quality biosimilar drugs (pioneering the biosimilar industry). He co-founded Celltrion in 2002, recognizing the structural opportunity to provide affordable generic biological drugs globally.

• Celltrion Group (Co-founder & Chairman): The core publicly traded asset, a major manufacturer of biopharmaceuticals and biosimilar drugs (e.g., Remsima, Truxima).
• Biotech Pioneer: His success is built on scale manufacturing and R&D in biosimilar technology, successfully competing with global pharmaceutical majors.
• Academic Background: He holds an M.B.A. from KAIST.
• Investment Strategy: His philosophy is rooted in long-term investment in biomedical R&D and leveraging the massive global demand for affordable biopharmaceuticals.

Seo Jung-jin's strategic genius was his commitment to cost-effective innovation. He previously worked at Samsung SDI. He founded Celltrion in 2002, successfully building it into a global force by specializing in high-volume manufacturing of biosimilars. His structural contribution is immense: pioneering the scale manufacturing and professionalization of the biosimilar sector in South Korea and globally, making it a foundation of the global healthcare supply chain.

The company successfully executed its IPO on the KOSDAQ. He has announced several retirement/re-entry transitions (reflecting his dedication to the company's long-term strategy). His wealth is secured by the colossal, long-term, stable profitability of the global biopharmaceutical sector.

Seo Jung-jin's social impact stems from Celltrion's role in providing essential, affordable biosimilar drugs, which significantly improve treatment access for millions globally, particularly for chronic diseases like cancer and autoimmune disorders. He has committed significant personal wealth to philanthropic causes focused on poverty and global health.

His personal philanthropy supports various community and educational initiatives.

Seo Jung-jin maintains the professional, composed style of a corporate executive. His attire is consistently formal and high-quality, favoring tailored suits. His aesthetic reflects serious authority and stability, typical of a leader in the specialized biotechnology sector.

Residing in Incheon, South Korea, his luxury is the immense security and financial reward derived from his multi-billion dollar fortune. His life is dedicated to biotechnology innovation, strategic management, and the long-term stewardship of the Celltrion empire.